Burn Pain – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
![]() |
Pain
associated with burn and discomfort is an unfortunate part of burn injury and
recovery. Burn pain is complex and requires careful assessment by your health
care provider to find the best treatment. Pain management often requires a
multidisciplinary approach that may include both medication and non-medication
treatments and involve a team of health providers. There are many different
types of burn pain, and each person’s pain is unique. Understanding your pain
type, intensity, and duration is essential for treatment. Types of pain are
classified as Acute pain, Breakthrough pain, Resting pain, Chronic Pain, and
Neuropathic Pain. It is often difficult to distinguish between changes in
background pain and additional pain caused by movement, both of which would be
regarded as ‘breakthrough pain.’ For this reason, breakthrough pain has been
dealt with alongside background pain.
According
to a literature survey, 1.1 million burn injuries require medical attention
each year in the United States. Approximately 50,000 of these require
hospitalization; 20,000 have significant burns involving at least 25 percent of
their total body surface, and about 4,500 die. Up to 10,000 people in the
United States die every year of burn-related infections.
The
competitive landscape includes country-specific approved and pipeline
therapies. Any asset/product-specific designation or review and Accelerated
Approval are tracked and supplemented with analyst commentary.
KOLs insights of Burn Pain
across 8 MM market from the center of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm, and Unmet
needs.
Burn
Pain Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 MW-III Skingenix,
Inc. Phase 2
2 DGD MediWound Ltd Phase 2
3 Autologous Engineered Skin Substitute Amarantus BioScience Phase 2
4 StrataGraft Skin Tissue Stratatech,
a Mallinckrodt Company Phase 1

Comments
Post a Comment